When Breathing Doesn’t Come Easy

Asthma accounts for a quarter of a million deaths annually worldwide. In the US, asthma accounted for almost 13 million missed school days, and more than 10 million missed work days. The economic and societal burden is immense.
When Breathing Doesn’t Come Easy


According to the WHO, an additional 65 million people have moderate to severe chronic obstructive pulmonary disease (COPD). More than 3 million people die of COPD each year - the fifth leading cause of death globally. The WHO expects COPD to become the world’s third-leading cause of death by 2030.

Asthma is manageable. There are two key issues, and this is where Teva is focused. They are 1) treatment adherence and compliance, and 2) treating asthma when it is not controlled despite the use of optimal therapy.

We are a major player in the treatment of respiratory disorders. We are developing new treatment options for patients based on the combination of our integrated strengths in specialty medicines (including both small molecules and biologics), device platforms and generics. This is creating a broad pipeline of intuitive, effective and accessible treatment options for patients, doctors and healthcare providers.

Putting the Brakes on Uncontrolled Asthma
10% of the world’s 300 million people suffer from uncontrolled asthma despite optimized therapy. This leads to reduced lung function, nocturnal symptoms, activity limitation and exacerbation.

7% of these patients are hospitalized overnight due to acute attacks. In the EU alone, this costs $20B a year. Asthma exacerbation is often caused by the proliferation of pro-inflammatory cells called eosinophils. A protein known as Interleukin-5 (IL-5) plays a key role in the production and role of eosinophils. We have developed a monoclonal antibody (biologic treatment), that specifically targets IL-5 in order to interrupt the production of these cells that may lead to asthma exacerbations.